World Class Bodybuilding   Forum

BulkSupplements Egg Whites International A1Supplements.com i-Supplements Strength.com VitaSprings Myprotein Beyondsupplements
Go Back   World Class Bodybuilding Forum > WorldClass RSS Feeds > Testosterone RSS feeds

Shoutbox
Loading...





Reply
 
Thread Tools Search this Thread Display Modes
  #1  
Old 03-16-2019, 05:20 AM
basskiller's Avatar
basskiller basskiller Is Off Line
Administrator

 
Join Date: Jan 2004
Location: Bodybuilding heaven
Posts: 128,063
Thanks: 3,517
Thanked 18,619 Times in 10,800 Posts
Rep Power: 4280
basskiller has a reputation beyond reputebasskiller has a reputation beyond reputebasskiller has a reputation beyond reputebasskiller has a reputation beyond reputebasskiller has a reputation beyond reputebasskiller has a reputation beyond reputebasskiller has a reputation beyond reputebasskiller has a reputation beyond reputebasskiller has a reputation beyond reputebasskiller has a reputation beyond reputebasskiller has a reputation beyond repute
rss A multicenter observational study of the real-world use of docetaxel for metastatic c

Related Articles A multicenter observational study of the real-world use of docetaxel for metastatic castration-resistant prostate cancer in China.

Asia Pac J Clin Oncol. 2019 Mar 15;:

Authors: He D, Sun Z, Guo J, Zhang Z, Shan Y, Ma L, Li H, Jin J, Huang Y, Xiao J, Wei Q, Ye D

Abstract
AIM: To investigate the use of docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in real-world clinical practice in China.
METHODS: This single-arm, prospective, observational study was conducted at 32 study centers in China and included male patients aged >=18 years with histologically confirmed prostate cancer who received >=1 dose of docetaxel following failure of hormonal therapy (disease progression with serum testosterone =third-line (12.7% [51]) hormonal therapy, estramustine (11.4% [46]) or other (2.7% [11]). The planned cycles of docetaxel therapy were completed by 30.8% of patients, and the mean (SD) number of cycles received was 4.4 (2.86). Median overall survival (mOS) was 22.4 (95% CI, 20.4-25.8) months and the prostate-specific antigen (PSA) response rate in patients with available data was 70.9% (168/237), with no differences in mOS and PSA response rates between treatment settings. Subgroup analysis revealed higher mOS in patients without visceral metastasis versus those with such metastases (22.9 vs. 17.4 months; P.=.0.022). No new safety signals were observed and the most common adverse events associated with docetaxel were granulocytopenia (5%) and leukopenia (4.5%).
CONCLUSION: Data from this study showed that around three-quarters of Chinese patients with mCRPC treated with docetaxel initiated treatment following first- or second-line hormonal therapy and no new safety signals were observed.


PMID: 30873737 [PubMed - as supplied by publisher]



This is an automated post
__________________

W C B B Sponsors
Southern Sarms

Beyondsupplements
Myprotein.com
Strength.com
i-Supplements
A1Supplements.com
BulkSupplements.com
Egg Whites International <---100% Bio-Available Egg White Protein


Remember... Any advice given on this board is just an opinion and not to be taken as medical advice. WCBB doesn't advocate or condone use of steroids. Check the laws in your country. WCBB just provides the platform in which to discuss such matters
Reply With Quote
Get your liquid egg whites here at EGG WHITES INTERNATIONAL

Reply

Bookmarks


Currently Active Users Viewing This Thread: 2 (0 members and 2 guests)
 
Thread Tools Search this Thread
Search this Thread:

Advanced Search
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -5. The time now is 05:09 AM.



Copyright ©2000 - 2019, Jelsoft Enterprises Ltd.
follow worldclassbodybuilding at facebook follow worldclassbodybuilding at pinterest follow worldclassbodybuilding at twitter